Who founded Sensorium Therapeutics?

Sensorium Therapeutics was founded by Jerrold Rosenbaum, Jacob Hooker in 2021.

Who are Sensorium Therapeutics's investors?

Sensorium Therapeutics's investors include Bonaventure Equity, LLC, Hatteras Venture Partners, Iter Investments, Mission Biocapital, Route 66 Ventures, Service Provider Capital, Sante Health Ventures.

How much funding has Sensorium Therapeutics raised?

Sensorium Therapeutics has disclosed $60.5M raised across 3 rounds.

Where is Sensorium Therapeutics headquartered?

Sensorium Therapeutics is headquartered in Medford, US.

Sensorium Therapeutics

Medford, US · Founded 2021 · Delaware corporation · 27 employees on LinkedIn · 7 known investors

Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.

AI & Machine Learning Biotech Digital Health

Founders & leadership

Sensorium Therapeutics was founded in 2021 by Jerrold Rosenbaum and Jacob Hooker.

Jerrold Rosenbaum inCo-Founder, DirectorJerrold Rosenbaum is the Stanley Cobb Professor of Psychiatry at Harvard Medical School, where he chaired the psychiatry department for two decades until 2019, and directs the MGH Center for Neuroscience of Psychedelics; a Yale College and Yale Medical School graduate who trained in psychiatry at Massachusetts General Hospital, he co-founded Sensorium Therapeutics to develop psychiatric therapeutics from plant-derived molecules.

Jacob Hooker inCo-FounderJacob Hooker is a scientist with an academic research background in neuroscience who works as a biotech entrepreneur and executive. He is an Executive Officer and Director of Sensorium Therapeutics, a clinical-stage biotech developing CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform.

Pranav TadiNamed on SEC filing

Board

Ryan Katz inBoard MemberFounding Partner at Route 66 Ventures

Kevin Lalande inBoard directorFounding Managing Director and CIO at Sante Ventures

Richard SimonBoard director

Balkrishan GillBoard director

Alexandra GlucksmannBoard director

Investors · 7

Bonaventure Equity, LLCRaleigh

Hatteras Venture PartnersResearch Triangle · $500K – $4M

Iter InvestmentsSouth Florida

Mission BiocapitalSan Francisco · $500K

Route 66 VenturesAlexandria · $500K – $4M

Service Provider CapitalVail

Sante Health VenturesreportedAustin

Reported raises · per SEC filings

Form D private placements

$60.5M disclosed across 3 rounds · 2021–2025

▶$26.8MraisedJul 2025 · 19 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Jerrold RosenbaumDirector
Ryan KatzDirector
Kevin LalandeDirector
Richard SimonDirector
Balkrishan GillDirector
Alexandra GlucksmannDirector
Jacob HookerExecutive Officer, Director

Offering amount: $58.5M
Amount sold: $26.8M
Proceeds to insiders: $531K
First sale: Jan 2025
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$24.7MraisedDec 2023 · 64 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Richard SimonExecutive Officer, Director
Pranav TadiExecutive Officer
Jerrold RosenbaumDirector
Kevin LalandeDirector
Ryan KatzDirector

Offering amount: $24.8M
Amount sold: $24.7M
Proceeds to insiders: $750K
First sale: Sep 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9MraisedJul 2021 · 47 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Richard SimonExecutive Officer, Director
Jerrold RosenbaumDirector
Pranav TadiExecutive Officer

Offering amount: $9M
Amount sold: $9M
Proceeds to insiders: $400K
First sale: Jul 2021
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld18 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Sensorium Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Sensorium Therapeutics Raises $25M in Series A Fundingfinsmes.com · Aug 2025

Sensorium Therapeutics Closes $30 Million Series A to Transform Mental Health Treatment with Nature-Inspired Psychoactive Medicinesprnewswire.com · Nov 2022

Frequently asked questions

What does Sensorium Therapeutics do?: Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
Who founded Sensorium Therapeutics?: Sensorium Therapeutics was founded by Jerrold Rosenbaum, Jacob Hooker in 2021.
Who are Sensorium Therapeutics's investors?: Sensorium Therapeutics's investors include Bonaventure Equity, LLC, Hatteras Venture Partners, Iter Investments, Mission Biocapital, Route 66 Ventures, Service Provider Capital, Sante Health Ventures.
How much funding has Sensorium Therapeutics raised?: Sensorium Therapeutics has disclosed $60.5M raised across 3 rounds.
Where is Sensorium Therapeutics headquartered?: Sensorium Therapeutics is headquartered in Medford, US.